Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension

Chest

Volumn 136, Issue 1, 2009, Pages 10-15

  Mejía, Mayra ^a   Carrillo, Guillermo ^a   Rojas Serrano, Jorge ^a,b   Estrada, Andrea ^a   Suárez, Teresa ^a   Alonso, Delfino ^a   Barrientos, Emilio ^a   Gaxiola, Miguel ^a   Navarro, Carmen ^a   Selman, Moisés ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EXERCISE; FEMALE; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN SATURATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REST; SEX RATIO; SMOKING; SURVIVAL RATE;

EID: 67650786507     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2306     Document Type: Article

References (22)

1. Selman M, Thannickal VJ, Pardo A, et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64:405- 430
2. Egan JJ, Martinez FJ, Wells AU, et al. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60:270-273
3. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157:1063-1072
4. Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62:62-66
5. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007; 2:e482
6. Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3:315-321
7. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542
8. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84:365-369
9. Cottin V, Nunes H, Brillet P, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26:586-593
10. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am J Respir Crit Care Med 2000; 161:646-664
11. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171-1181
12. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963-967
13. Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114:507-512
14. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70:657-662
15. Kinsella M, Mü ller NL, Abboud RT, et al. Quantitation of emphysema by computed tomography using a density mask program and correlation with pulmonary function tests. Chest 1990; 97:315-321
16. Kazerooni E, Martinez F, Flint A, et al. Thin section CT obtained at 10 mm increments versus limited three level thin section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169:977-983
17. Cottin V, Brillet PY, Nunes H, et al. Combined pulmonary fibrosis and emphysema. Presse Med 2007; 36:936-944
18. Selman M. The spectrum of smoking related interstitial lung disorders: the never ending story of smoke and disease. Chest 2003; 124:1185-1187
19. Lundblad LK, Thompson-Figueroa J, Leclair T, et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005; 171:1363-1370
20. Hoyle GW, Li J, Finkelstein JB, et al. Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol 1999; 154:1763-1775
21. Rogliani P, Mura M, Mattia P, et al. HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. Respir Med 2008; 102:1753-1761
22. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31:1334-1356